This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inspire Medical Systems (INSP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 20% and 14.19%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Inspire (INSP) Soars 7.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Inspire (INSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
3 Medical Info System Stocks to Gain on Rising Demand for Digital Health
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems, Inc. (INSP), Axonics (AXNX), and Pulmonx Corporation (LUNG) are expected to gain on rising demand for telehealth.
Wall Street Analysts Believe Inspire (INSP) Could Rally 46%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 46.4% upside potential for Inspire (INSP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CareCloud, Inc. (MTBC) Surges 11%: Is This an Indication of Further Gains?
by Zacks Equity Research
CareCloud, Inc. (MTBC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Inspire (INSP) Stock Jumps 5.6%: Will It Continue to Soar?
by Zacks Equity Research
Inspire (INSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Inspire Medical Systems (INSP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 10.17% and 15.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 21.79% and 6.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Inspire Medical Systems (INSP) Q1 Earnings Expected to Decline
by Zacks Equity Research
Inspire (INSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inspire Medical Systems (INSP) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 80.85% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Inspire Medical (INSP) Might Surprise This Earnings Season
by Zacks Equity Research
Inspire Medical (INSP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Inspire Medical Systems (INSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Inspire (INSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inspire Medical Systems (INSP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 37.70% and 10.90%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Inspire Medical Systems (INSP) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Inspire (INSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner
by Zacks Equity Research
Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner
Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges
by Urmimala Biswas
Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.
Inspire Medical Systems (INSP) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 21.31% and 17.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Inspire Medical Systems (INSP) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Inspire (INSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 7.69% and 9.18%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 37.78% and 10.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
NextGen (NXGN) Solution Acts as Financial Bridge Amid COVID-19
by Zacks Equity Research
NextGen's (NXGN) cloud-based EHR platform, NextGen Office, enables specialty practices to improve their financial performance during the pandemic.
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Inspire Medical Systems (INSP) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 45.07% and 59.33%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?